Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer
Between 4 and 15 ng/ml serum prostate-specific antigen (PSA) has a low specificity for prostate cancer (PCa). One accepted method to enhance this specificity is transrectal ultrasonography (TRUS)-measured PSA-density (PSA-D). We compared this method with a new alternative, transition zone PSA (PSA-T...
Gespeichert in:
| Veröffentlicht in: | European journal of ultrasound 1998-11, Vol.8 (2), p.125-128 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 128 |
|---|---|
| container_issue | 2 |
| container_start_page | 125 |
| container_title | European journal of ultrasound |
| container_volume | 8 |
| creator | Michielsen, Dirk P.J De Boe, Veerle R Braeckman, Johan G Keuppens, Frans I |
| description | Between 4 and 15 ng/ml serum prostate-specific antigen (PSA) has a low specificity for prostate cancer (PCa). One accepted method to enhance this specificity is transrectal ultrasonography (TRUS)-measured PSA-density (PSA-D). We compared this method with a new alternative, transition zone PSA (PSA-TZ). We measured total and transition zone prostatic volumes by TRUS and calculated PSA-D and PSA-TZ in 59 patients with suspicion of PCa and PSA between 4 and 15 ng/ml. All patients then had sextant biopsies of the prostate, 30 were positive for PCa and 29 showed benign tissue. With a cut-off value of 0.35, PSA-TZ had a positive predicted value of 77% for PCa, whereas PSA-D, with a cut-off value of 0.12, had a positive predicted value of 55%. Our data suggest PSA-TZ to be more reliable for avoiding unnecessary biopsies in patients with PCa suspicion and serum PSA below 15 ng/ml. PSA-TZ, calculated by TRUS, enhances the specificity of PSA for needle biopsy diagnosis of PCa. |
| doi_str_mv | 10.1016/S0929-8266(98)00064-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70113491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0929826698000640</els_id><sourcerecordid>70113491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c304t-2859f7cfc0eedff6b82eb54ada5145019322049355179860bbd267b9915e0f663</originalsourceid><addsrcrecordid>eNqFkEtP4zAUhb0A8Zr5CUheIASLMNeJ7cQrhBAvCWlG03ZtOfY1GLVJsROk8utxaWGWs7Kuz7nnHn2EHDO4YMDkrwmoUhVNKeWZas4BQPICdsjB9_c-OUzpBbKXg9gje6rholb8gLxOlmiDDzYMK2o6R421YzR2RXtPp39nk2KBJo0RHf0zuSocdunLOUSzHkLf0fe-wyLrNHR0eEbqgnnq-hTSOmUZ-zSYAak1ncX4g-x6M0_4c_sekdntzfT6vnj8ffdwffVY2Ar4UJSNUL623gKi8162TYmt4MYZwbgApqqyBK4qIVitGglt60pZt0oxgeClrI7I6SY3338dMQ16EZLF-dx02I9J18BYxRXLRrEx2lw0RfR6GcPCxJVmoNd49SdeveaoVaM_8WrIe8fbA2O7QPe9tWWb9ZOtbpI1c59x2ZD-hUuWC6hsu9zYMMN4Cxh1sgEzKRci2kG7PvynyAcwfZjD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70113491</pqid></control><display><type>article</type><title>Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Michielsen, Dirk P.J ; De Boe, Veerle R ; Braeckman, Johan G ; Keuppens, Frans I</creator><creatorcontrib>Michielsen, Dirk P.J ; De Boe, Veerle R ; Braeckman, Johan G ; Keuppens, Frans I</creatorcontrib><description>Between 4 and 15 ng/ml serum prostate-specific antigen (PSA) has a low specificity for prostate cancer (PCa). One accepted method to enhance this specificity is transrectal ultrasonography (TRUS)-measured PSA-density (PSA-D). We compared this method with a new alternative, transition zone PSA (PSA-TZ). We measured total and transition zone prostatic volumes by TRUS and calculated PSA-D and PSA-TZ in 59 patients with suspicion of PCa and PSA between 4 and 15 ng/ml. All patients then had sextant biopsies of the prostate, 30 were positive for PCa and 29 showed benign tissue. With a cut-off value of 0.35, PSA-TZ had a positive predicted value of 77% for PCa, whereas PSA-D, with a cut-off value of 0.12, had a positive predicted value of 55%. Our data suggest PSA-TZ to be more reliable for avoiding unnecessary biopsies in patients with PCa suspicion and serum PSA below 15 ng/ml. PSA-TZ, calculated by TRUS, enhances the specificity of PSA for needle biopsy diagnosis of PCa.</description><identifier>ISSN: 0929-8266</identifier><identifier>DOI: 10.1016/S0929-8266(98)00064-0</identifier><identifier>PMID: 9845794</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Biopsy, Needle ; Diagnosis, Differential ; Humans ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Predictive Value of Tests ; Prostate cancer ; Prostate-Specific Antigen - analysis ; Prostatic Neoplasms - chemistry ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - pathology ; PSA ; PSA-density ; PSA-transition zone ; Rectum - diagnostic imaging ; Reproducibility of Results ; Retrospective Studies ; Sensitivity and Specificity ; Tumors of the urinary system ; Ultrasonography ; Ultrasound ; Urinary tract. Prostate gland</subject><ispartof>European journal of ultrasound, 1998-11, Vol.8 (2), p.125-128</ispartof><rights>1998 Elsevier Science Ireland Ltd</rights><rights>1999 INIST-CNRS</rights><rights>Copyright 1998 Elsevier Science Ireland Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c304t-2859f7cfc0eedff6b82eb54ada5145019322049355179860bbd267b9915e0f663</citedby><cites>FETCH-LOGICAL-c304t-2859f7cfc0eedff6b82eb54ada5145019322049355179860bbd267b9915e0f663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1611139$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9845794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Michielsen, Dirk P.J</creatorcontrib><creatorcontrib>De Boe, Veerle R</creatorcontrib><creatorcontrib>Braeckman, Johan G</creatorcontrib><creatorcontrib>Keuppens, Frans I</creatorcontrib><title>Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer</title><title>European journal of ultrasound</title><addtitle>Eur J Ultrasound</addtitle><description>Between 4 and 15 ng/ml serum prostate-specific antigen (PSA) has a low specificity for prostate cancer (PCa). One accepted method to enhance this specificity is transrectal ultrasonography (TRUS)-measured PSA-density (PSA-D). We compared this method with a new alternative, transition zone PSA (PSA-TZ). We measured total and transition zone prostatic volumes by TRUS and calculated PSA-D and PSA-TZ in 59 patients with suspicion of PCa and PSA between 4 and 15 ng/ml. All patients then had sextant biopsies of the prostate, 30 were positive for PCa and 29 showed benign tissue. With a cut-off value of 0.35, PSA-TZ had a positive predicted value of 77% for PCa, whereas PSA-D, with a cut-off value of 0.12, had a positive predicted value of 55%. Our data suggest PSA-TZ to be more reliable for avoiding unnecessary biopsies in patients with PCa suspicion and serum PSA below 15 ng/ml. PSA-TZ, calculated by TRUS, enhances the specificity of PSA for needle biopsy diagnosis of PCa.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biopsy, Needle</subject><subject>Diagnosis, Differential</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Predictive Value of Tests</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - analysis</subject><subject>Prostatic Neoplasms - chemistry</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - pathology</subject><subject>PSA</subject><subject>PSA-density</subject><subject>PSA-transition zone</subject><subject>Rectum - diagnostic imaging</subject><subject>Reproducibility of Results</subject><subject>Retrospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Tumors of the urinary system</subject><subject>Ultrasonography</subject><subject>Ultrasound</subject><subject>Urinary tract. Prostate gland</subject><issn>0929-8266</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtP4zAUhb0A8Zr5CUheIASLMNeJ7cQrhBAvCWlG03ZtOfY1GLVJsROk8utxaWGWs7Kuz7nnHn2EHDO4YMDkrwmoUhVNKeWZas4BQPICdsjB9_c-OUzpBbKXg9gje6rholb8gLxOlmiDDzYMK2o6R421YzR2RXtPp39nk2KBJo0RHf0zuSocdunLOUSzHkLf0fe-wyLrNHR0eEbqgnnq-hTSOmUZ-zSYAak1ncX4g-x6M0_4c_sekdntzfT6vnj8ffdwffVY2Ar4UJSNUL623gKi8162TYmt4MYZwbgApqqyBK4qIVitGglt60pZt0oxgeClrI7I6SY3338dMQ16EZLF-dx02I9J18BYxRXLRrEx2lw0RfR6GcPCxJVmoNd49SdeveaoVaM_8WrIe8fbA2O7QPe9tWWb9ZOtbpI1c59x2ZD-hUuWC6hsu9zYMMN4Cxh1sgEzKRci2kG7PvynyAcwfZjD</recordid><startdate>199811</startdate><enddate>199811</enddate><creator>Michielsen, Dirk P.J</creator><creator>De Boe, Veerle R</creator><creator>Braeckman, Johan G</creator><creator>Keuppens, Frans I</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199811</creationdate><title>Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer</title><author>Michielsen, Dirk P.J ; De Boe, Veerle R ; Braeckman, Johan G ; Keuppens, Frans I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c304t-2859f7cfc0eedff6b82eb54ada5145019322049355179860bbd267b9915e0f663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biopsy, Needle</topic><topic>Diagnosis, Differential</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Predictive Value of Tests</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - analysis</topic><topic>Prostatic Neoplasms - chemistry</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - pathology</topic><topic>PSA</topic><topic>PSA-density</topic><topic>PSA-transition zone</topic><topic>Rectum - diagnostic imaging</topic><topic>Reproducibility of Results</topic><topic>Retrospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Tumors of the urinary system</topic><topic>Ultrasonography</topic><topic>Ultrasound</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michielsen, Dirk P.J</creatorcontrib><creatorcontrib>De Boe, Veerle R</creatorcontrib><creatorcontrib>Braeckman, Johan G</creatorcontrib><creatorcontrib>Keuppens, Frans I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of ultrasound</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michielsen, Dirk P.J</au><au>De Boe, Veerle R</au><au>Braeckman, Johan G</au><au>Keuppens, Frans I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer</atitle><jtitle>European journal of ultrasound</jtitle><addtitle>Eur J Ultrasound</addtitle><date>1998-11</date><risdate>1998</risdate><volume>8</volume><issue>2</issue><spage>125</spage><epage>128</epage><pages>125-128</pages><issn>0929-8266</issn><abstract>Between 4 and 15 ng/ml serum prostate-specific antigen (PSA) has a low specificity for prostate cancer (PCa). One accepted method to enhance this specificity is transrectal ultrasonography (TRUS)-measured PSA-density (PSA-D). We compared this method with a new alternative, transition zone PSA (PSA-TZ). We measured total and transition zone prostatic volumes by TRUS and calculated PSA-D and PSA-TZ in 59 patients with suspicion of PCa and PSA between 4 and 15 ng/ml. All patients then had sextant biopsies of the prostate, 30 were positive for PCa and 29 showed benign tissue. With a cut-off value of 0.35, PSA-TZ had a positive predicted value of 77% for PCa, whereas PSA-D, with a cut-off value of 0.12, had a positive predicted value of 55%. Our data suggest PSA-TZ to be more reliable for avoiding unnecessary biopsies in patients with PCa suspicion and serum PSA below 15 ng/ml. PSA-TZ, calculated by TRUS, enhances the specificity of PSA for needle biopsy diagnosis of PCa.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>9845794</pmid><doi>10.1016/S0929-8266(98)00064-0</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-8266 |
| ispartof | European journal of ultrasound, 1998-11, Vol.8 (2), p.125-128 |
| issn | 0929-8266 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70113491 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - blood Biopsy, Needle Diagnosis, Differential Humans Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Predictive Value of Tests Prostate cancer Prostate-Specific Antigen - analysis Prostatic Neoplasms - chemistry Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology PSA PSA-density PSA-transition zone Rectum - diagnostic imaging Reproducibility of Results Retrospective Studies Sensitivity and Specificity Tumors of the urinary system Ultrasonography Ultrasound Urinary tract. Prostate gland |
| title | Specificity and accuracy of TRUS-measured PSA-density and transition zone-PSA in the diagnosis of prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A21%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Specificity%20and%20accuracy%20of%20TRUS-measured%20PSA-density%20and%20transition%20zone-PSA%20in%20the%20diagnosis%20of%20prostate%20cancer&rft.jtitle=European%20journal%20of%20ultrasound&rft.au=Michielsen,%20Dirk%20P.J&rft.date=1998-11&rft.volume=8&rft.issue=2&rft.spage=125&rft.epage=128&rft.pages=125-128&rft.issn=0929-8266&rft_id=info:doi/10.1016/S0929-8266(98)00064-0&rft_dat=%3Cproquest_cross%3E70113491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70113491&rft_id=info:pmid/9845794&rft_els_id=S0929826698000640&rfr_iscdi=true |